The problem we have right now with this fragmentation between the way we pay for drugs and the way we pay for other health care services in an establishment, in hospitals, is that we have a lot of cost-shifting. With the new wave of oral anti-cancer drugs, for example, we don't need to treat you in the hospital, but then you need to pay for your cancer drugs yourself.
Many of the cases we see.... Last week we had a study that showed that half of the new cancer drugs arriving in the market did not show any therapeutic benefit compared to what already exists. The thing is, if you have a new treatment that instead of requiring, let's say, 10 injections in a month, requires only four injections in a month, you can be sure that for the patient this is something more interesting, but if the price difference between four and 10 injections is $60,000 per month, then you need to ask whether we should be paying for that. Then you can say, “Well, this is fantastic. Private coverage does accept to pay for that.” In terms of cost-effectiveness, that might not be the best solution.